| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,444,302 ) |
| | 2025 | 2025 | SIGNABLOK, INC. | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43HL174220 | TREM-1 therapy for the treatment of empyema | 000 | 1 | NIH | 9/10/2025 | $457,954 |
| | 2025 | 2025 | SIGNABLOK, INC. | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R21AI193495 | Novel medical countermeasure to mitigate potentially lethal acute radiation syndrome | 000 | 1 | NIH | 9/18/2025 | $155,857 |
| | 2025 | 2025 | SIGNABLOK, INC. | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44EY034015 | First-in-class TREM-1 inhibitors for neovascular retinal diseases | 001 | 2 | NIH | 4/7/2025 | $830,491 |
| | 2025 | 2023 | SIGNABLOK, INC. | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43HL165734 | New mechanism-based TREM-1 therapy for acute respiratory distress syndrome | 000 | 1 | NIH | 12/30/2024 | $0 |
| | 2025 | 2023 | SIGNABLOK, INC. | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44EY034015 | First-in-class TREM-1 inhibitors for neovascular retinal diseases | 000 | 1 | NIH | 11/13/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | SIGNABLOK, INC. | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44EY034015 | First-in-class TREM-1 inhibitors for neovascular retinal diseases | 000 | 1 | NIH | 11/8/2023 | $0 |
| | 2024 | 2020 | SIGNABLOK, INC. | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44CA217400 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer | 000 | 3 | NIH | 2/5/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $550,868 ) |
| | 2023 | 2023 | SIGNABLOK, INC. | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43HL165734 | New mechanism-based TREM-1 therapy for acute respiratory distress syndrome | 000 | 1 | NIH | 7/31/2023 | $272,741 |
| | 2023 | 2023 | SIGNABLOK, INC. | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44EY034015 | First-in-class TREM-1 inhibitors for neovascular retinal diseases | 000 | 1 | NIH | 9/6/2023 | $278,127 |
| | 2023 | 2020 | SIGNABLOK, INC. | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43AR078110 | TREM-1 inhibitor for the treatment of scleroderma | 000 | 1 | NIH | 4/24/2023 | $0 |
| | 2023 | 2020 | SIGNABLOK, INC. | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44AR077456 | TREM-1 therapy for rheumatoid arthritis | 000 | 1 | NIH | 11/16/2022 | $0 |
| | 2023 | 2020 | SIGNABLOK INC | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44CA217400 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer | 000 | 3 | NIH | 3/31/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | SIGNABLOK INC | 61 FRANK ST | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44CA217400 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer | 000 | 3 | NIH | 6/30/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2020 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44AR077456 | TREM-1 therapy for rheumatoid arthritis | 000 | 1 | NIH | 11/18/2020 | $0 |
| | 2021 | 2020 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43AR078110 | TREM-1 inhibitor for the treatment of scleroderma | 000 | 1 | NIH | 3/8/2021 | $0 |
| | 2021 | 2018 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43GM128369 | Novel TREM-1 targeting therapies for sepsis | 000 | 1 | NIH | 2/1/2021 | $0 |
| | 2021 | 2018 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43GM128369 | Novel TREM-1 targeting therapies for sepsis | 001 | 1 | NIH | 8/29/2021 | $0 |
| | 2021 | 2018 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43EY028779 | Development of first-in-class TREM-1 inhibitors for neovascular retinal diseases | 000 | 1 | NIH | 9/15/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,706,450 ) |
| | 2020 | 2020 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44AR077456 | TREM-1 therapy for rheumatoid arthritis | 000 | 1 | NIH | 9/9/2020 | $258,603 |
| | 2020 | 2020 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44CA217400 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer | 001 | 3 | NIH | 9/4/2020 | $1,198,246 |
| | 2020 | 2020 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43AR078110 | TREM-1 inhibitor for the treatment of scleroderma | 000 | 1 | NIH | 9/10/2020 | $249,601 |
| | 2020 | 2019 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44CA217400 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer | 000 | 2 | NIH | 1/14/2020 | $0 |
| | 2020 | 2018 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43GM128369 | Novel TREM-1 targeting therapies for sepsis | 000 | 1 | NIH | 4/24/2020 | $0 |
| | 2020 | 2018 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43EY028779 | Development of first-in-class TREM-1 inhibitors for neovascular retinal diseases | 000 | 1 | NIH | 7/13/2020 | $0 |
| | 2020 | 2017 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43CA217400 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer | 000 | 1 | NIH | 8/31/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $801,644 ) |
| | 2019 | 2019 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43CA217400 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer | 002 | 1 | NIH | 9/24/2019 | $0 |
| | 2019 | 2019 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44CA217400 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer | 000 | 2 | NIH | 9/25/2019 | $799,560 |
| | 2019 | 2019 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43CA217400 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer | 000 | 1 | NIH | 8/13/2019 | $2,084 |
| | 2019 | 2018 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43GM128369 | Novel TREM-1 targeting therapies for sepsis | 000 | 1 | NIH | 2/7/2019 | $0 |
| | 2019 | 2017 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43CA217400 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer | 001 | 1 | NIH | 9/24/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $451,219 ) |
| | 2018 | 2018 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43GM128369 | Novel TREM-1 targeting therapies for sepsis | 000 | 1 | NIH | 8/23/2018 | $224,996 |
| | 2018 | 2018 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43EY028779 | Development of first-in-class TREM-1 inhibitors for neovascular retinal diseases | 001 | 1 | NIH | 7/9/2018 | $224 |
| | 2018 | 2018 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43EY028779 | Development of first-in-class TREM-1 inhibitors for neovascular retinal diseases | 000 | 1 | NIH | 5/17/2018 | $225,999 |
| | 2018 | 2016 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43AA024355 | Treatment of alcoholic liver disease with novel targeted inhibitors | 000 | 1 | NIH | 7/13/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $224,672 ) |
| | 2017 | 2017 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43CA217400 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer | 000 | 1 | NIH | 9/21/2017 | $224,672 |
| | 2017 | 2015 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R43CA195684 | Development of novel targeted agents in pancreatic cancer | 000 | 1 | NIH | 5/8/2017 | $0 |
| | 2017 | 2015 | SIGNABLOK, INC. | 61 FRANK ST APT 36 | WORCESTER | MA | 01604-1000 | WORCESTER | USA | R44HL110417 | Multifunctional nanoformulations for diagnostic imaging of atherosclerosis | 000 | 3 | NIH | 7/28/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $223,443 ) |
| | 2016 | 2016 | SIGNABLOK INC | POST OFFICE BOX 4064 | SHREWSBURY | MA | 01545 | WORCESTER | USA | R43AA024355 | Treatment of alcoholic liver disease with novel targeted inhibitors | 000 | 1 | NIH | 9/5/2016 | $223,443 |
|
| Issue Date FY: 2015 ( Subtotal = $893,102 ) (Continued on the next page) |
| | 2015 | 2015 | SIGNABLOK INC | POST OFFICE BOX 4064 | SHREWSBURY | MA | 01545 | WORCESTER | USA | R43CA195684 | Development of novel targeted agents in pancreatic cancer | 000 | 1 | NIH | 8/13/2015 | $219,937 |
|
